The reduction of N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 15% more than placebo, this being an important change in a surrogate marker for improving heart function
This approach is only appropriate for individuals who have previously tolerated GLP-1 agonists
These additives do not change the tirzepatide concentration listed on the label
Sources Food and Drug Administration (FDA): FDA Approves New Medication for Chronic Weight Management Molecular Metabolism Journal: Glucagon-like peptide 1 (GLP-1) American Gastroenterological Association (AGA): Biology of Incretins: GLP-1 and GIP Columbia Surgery: The Ozempic Effect: Everything You Need to Know About Medical Weight Loss Eli Lilly: Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies American Diabetes Association (ADA): Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes Important Medical Information and Disclaimers Important Current Status Update : As of March 19, 2025, the FDA has ended enforcement discretion for compounded tirzepatide
Weve worked with thousands of people who were stuck between a rock and a hard place, Ozempic on one side, acid reflux on the other
However, it should be noted that patients may evaluate drugs differently during actual treatment, and the impact of these various factors in practice may be less than patients anticipate
